AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02068690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809 PfOS
Description: BI 425809 PfOS
Study NCT02068690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT02068690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809 tablet
Description: BI 425809 tablet
Study NCT02182063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120 low dose
Study NCT02182063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120 high dose
Study NCT01950793 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: triamcinolone acetonide
Description: used ultrasound-guided inject 1c.c triamcinolone acetonide 10mg/mL (Shincort®, YSP, Taiwan)into the sheath of the flexor tendons, penetrated to the A1 pulley.~One injection only Steroid
Study NCT01950793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid
Description: used ultrasound-guided inject 1c.c Hyaluronic acid (Artz®, Seikagaku, Japan)into the sheath of the flexor tendons, penetrated to the A1 pulley.~One injection only
Study NCT03929653 — intervention group
Intervention type: OTHER
Intervention: Personalized therapy model with Molecular Tumor Board and Next Generation Sequencing
Description: This study is to observe this therapy model outcomes
Study NCT02570152 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample collection
Description: Blood samples will be collected during the Suspected Dengue First Visit. All study subjects with AFI (fever \[body temperature ≥ 38°C/≥ 100.4°F\] on ≥ 2 consecutive calendar days, measured at least twice, at least 8 hours apart) should be seen at a designated study hospital/clinic by the study physician. The Suspected Dengue First Visit should be scheduled within 7 days from the onset of fever (Days 2-7) and should ideally take place on the second day of fever (Day 2).
Study NCT03564522 — intervention group
Intervention type: PROCEDURE
Intervention: cardiac catheterization
Description: cardiac catheterizations will be clinically indicated and the study will collect this clinical data.
Study NCT03564522 — intervention group
Intervention type: RADIATION
Intervention: Cardiac MRI
Description: If clinically indicated, the study will collect data from MRIs.
Study NCT03913026 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Transplant with an expanded ECT-001 cord blood
Description: 1. Patients will receive a conditioning regimen (such as: cyclophosphamide 120 mg/kg, fludarabine 75mg/m2 and TBI 12 Gy or cyclophosphamide 50 mg/kg, fludarabine 150 mg/m2, thiotepa 10 mg/kg and TBI 4 Gy).~2. The cord to be expanded will undergo CD34+ selection. The CD34- product is cryopreserved and will be thawed and infused on Day +1 post-transplant. The CD34+ product will be placed in a closed culture with UM171 for a 7-day expansion and is infused on Day 0.~3. Patients will receive standard supportive care and GVHD prophylaxis (such as MMF and tacrolimus). Tacrolimus will be discontinued on Day 100 post-transplant unless GVHD arises.
Study NCT02657655 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesia 360
Description: Kinesia 360 includes a mobile app and wireless motion sensors worn on the patient's wrist and ankle to quantify tremor, dyskinesias, and mobility throughout the day as he or she goes about normal activities. The app includes electronic diaries enable patients to rate their symptoms and log when medications are taken. Data is transferred to a cloud server where motor symptom reports are generated for clinician review.
Study NCT02017938 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Virtual Reality anti-fatigue ergo cycling training (Self-made)
Description: To establish a Virtual Reality systems to reduce fatigue of cycling training for PD subjects.
Study NCT01181999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: A dose of 375mg/m2 rituximab will be administered intravenously on day 1 of first to fourth R-CHOP chemotherapy and on day 1, 8, 15, 22 of each augmentation chemotherapy.
Study NCT00839449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid ethyl ester
Description: Orally administered 900 mg eicosapentaenoic acid ethyl ester three times a day (2700 mg ⁄ day) from the surgery next day to 30 days after the onset of SAH.
Study NCT02284529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orectalip
Description: Oxaliplatin 85mg/m2 in D5W 250 ml IV drip 2hrs on D1, Leucovorin 100mg/m2 in N/S 100ml IV drip 2hrs on D1, follow by 5-FU 2400mg/m2 IV infusion 24hrs on D1
Study NCT03915574 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 25G Dural Puncture Epidural
Description: Dural puncture created with a 25 gauge spinal needle
Study NCT03915574 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Epidural
Description: Control group - standard epidural (no dural puncture)
Study NCT02842515 — intervention group
Intervention type: OTHER
Intervention: teeth avulsion
Study NCT01213147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clomiphene citrate
Description: 100 mg per day oral for 7 days
Study NCT01213147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: buserelin
Description: 50 µg Subcutaneous twice a day from cycle day 2 of menstrual cycle
Study NCT00923975 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: DIDGET World Web Community Reports
Description: During the study subjects performed specific tasks, such as uploading meter results to a secure website and displaying reports.
Study NCT01328535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Given PO
Study NCT01328535 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative studies
Study NCT01328535 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: staining method
Description: Correlative studies
Study NCT01328535 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Optional correlative studies
Study NCT01328535 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT05384418 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HDP-Tc99m bone scintigraphy
Description: HDP-Tc99m bone scintigraphy
Study NCT03554057 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary Computed Tomographic Angiography
Description: All low-risk patients referred for invasive coronary angiography will be potentially eligible to receive the intervention over a 12-month period. The intervention will include risk stratification using Coronary Computed Tomographic Angiography (CCTA) at HHS and NHS as an alternative to upfront invasive angiography. All CCTAs will be read by both a level 3-trained cardiologist and a radiologist. The results of the CCTA, coupled with evidence-based management recommendations will be sent to the referring physician and an invasive angiogram will be arranged only when indicated as per these management recommendations
Study NCT03224507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRdD followed by auto-HCT
Description: Dosages of each drug will vary depending on therapy type and cycle number. KRdD therapy will be followed by autologous hematopoietic cell transplantation and KRdD consolidation.
Study NCT03224507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRdD only
Description: Dosages of each drug will vary depending on therapy type and cycle number. KRdD therapy will not be followed by autologous hematopoietic cell transplantation but will proceed with KRdD consolidation.
Study NCT00619424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib
Description: Oral tablet administered daily in dosages of 400 - 800 mg.
Study NCT00619424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: oral tablet taken daily in dosages of 100-150 mg.
Study NCT00619424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: IV chemotherapeutic agent administered every 21 days in dosages of 400-500 mg/m2
Study NCT01032291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Intravenous infusions of cetuximab (400 mg/m\^2 Cycle 1 Day 1, thereafter 250 mg/m\^2), administered on days 1, 8, 15 and 22 of each 28 day cycle.
Study NCT01032291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Daily oral lenalidomide 25mg on days 1 to 28 of each 28 day cycle
Study NCT00660413 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TOF-Watch SX (Acceleromyography)
Description: Randomization of AMG to dominant or non-dominant arm. MMG at contralateral arm.
Study NCT00660413 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TOF-Watch SX (Acceleromyography)
Description: Randomization of AMG to dominant or non-dominant arm. MMG at contralateral arm.
Study NCT03699059 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ExeRTiOn
Description: REHAB-online is an online weight gain prevention tool comprising of physical activity advice, dietetic advice, self-monitoring and tracking and behavioural change techniques. This resource is specific to kidney transplant patients and has been created by the research steering group including patient representation. During this study participants (both HCPs and patients) will have a one-off study visit to test and evaluate the online intervention.
Study NCT03600636 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Diffusion tensor imaging MRI
Description: 1. axial diffusion weighted sequence with 32 gradient encoding directions and two values b, 0 s / mm 2 and 1000 s / mm 2.~2. Fluid-attenuated inversion recovery~3. three-dimensional axial image weighted in T1~4. axial echo-planar image sequence~5. three-dimensional pulse sequence axial flight time
Study NCT02449889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: highly purified human chorionic gonadotropin
Study NCT02449889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant human chorionic gonadotropin
Study NCT03197714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPB-111077
Description: Two dose schemas will be employed:~* Level 1: 200 mg daily~* Level 2: 250 mg daily
Study NCT00797745 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: peginterferon alfa 2b
Description: 1.5 mcg/kg subcutaneously weekly for up to 24 or 48 weeks
Study NCT00797745 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: peginterferon alfa 2b
Description: 1.5 mcg/kg subcutaneously weekly for up to 24 or 48 weeks
Study NCT00797745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: ribavirin 600 to 1400 mg daily (weight-based dosing) by mouth twice daily for up to 24 or 48 weeks
Study NCT00797745 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ribavirin
Description: ribavirin 600 to 1400 mg daily (weight-based dosing) by mouth twice daily for up to 24 or 48 weeks
Study NCT00797745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 900518
Description: SCH 900518 100 mg tablets taken as 200 mg PO QD, 100 mg PO BID, 400 mg PO QD, or 600 mg PO QD for 12 weeks.
Study NCT00797745 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SCH 900518
Description: SCH 900518 100 mg tablets taken as 200 mg PO QD, 100 mg PO BID, 400 mg PO QD, or 600 mg PO QD for 12 weeks.
Study NCT00797745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: Ritonavir 100 mg capsules taken as 100 mg PO QD or 100 mg PO BID for 12 weeks.
Study NCT00936910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amphotericin B liposomal (Ambisome)
Description: After enrollment, antifungal therapy will be instituted consisting of both systemic and antifungal lock therapy. Systemic therapy will be amphotericin B liposomal (Ambisome) administered IV in a dose of 3-5 mg/kg/day (or other antifungal based upon standard of care) combined with antifungal lock therapy. The antifungal lock therapy consists of placing sufficient amphotericin B liposomal (Ambisome \[2 mg/ml\]) lock solution into the infected central venous catheter (CVC) and allowing it to dwell uninterruptedly for 8 to 12 hours per day for 10-14 days (largest CVC = 2.3 mL).
Study NCT03171623 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: globalagliatin hydrochloride
Description: orally administration, single dose
Study NCT03171623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: globalagliatin hydrochloride
Description: orally administration, single dose
Study NCT03171623 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: orally administration, single dose
Study NCT03495076 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline injection
Description: In the saline injection condition, acute neck pain will be induced via 0.5 ml hypertonic (5% NaCl) saline bolus injection which is a commonly used model of acute pain. Saline will be injected into the right (or left) trapezius muscle at the level of C7 cervical level. Injections will be performed by a physician under ultrasound imaging guidance to ensure that each single injection will be equally placed at the same depth. The side for the pain induction will be randomised across subjects. The place of needle insertion and corresponding point on the opposite side of the body will be covered by placing a small piece of adhesive plaster to ensure blinding.
Study NCT03495076 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Description: In the sham-injection condition (nocebo comparator), a real needle will be shown to the participants to imitate and produce the anticipation of a pain experience. A pinprick sensation will be produced by a weighted stimulus applied perpendicularly to the skin without piercing the skin. A stimulus of 512 millinewtons (mN) will be used to produce a pinprick sensation and activation of cutaneous nociceptors. Adhesive tapes covering stimulation points will also be provided. The stimuli will be applied in exactly the same spot as the real injection in previous experimental condition.
Study NCT00797745 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ritonavir
Description: Ritonavir 100 mg capsules taken as 100 mg PO QD or 100 mg PO BID for 12 weeks.
Study NCT05076916 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The effectiveness of the web-based education programme among cancer patients
Description: The web-based education program was introduced to the patients with cancer in the intervention group during face-to-face interviews. They were asked to examine the program for at least two hours a week for three months. During the follow-up period, the patients in the intervention group were called twice a week and reminded to use the education program. The researchers get in contact with the patients online via the website. The patients contact the research team by calling or writing messages via the website 24/7. An e-mail account was created by the research team using the email system of the university, and it was shared with the patients. The clinical researchers of the team answered the patients' questions via this e-mail account.
Study NCT01415648 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cerebral oximetry monitoring using INVOS™ and hemodynamic optimisation
Description: continuous per operative cerebral oximetry monitoring associated with hemodynamic optimisation algorithm (excluding norepinephrine) if cerebral oximetry decrease more than 15% under the preoperative baseline
Study NCT01415648 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: standard cerebral monitoring and hemodynamic optimisation
Description: the patient is continously monitored with cerebral oximeter but this latter is blinded to the medical team, the alarm switch off , and patients are managed with the standard care of the centre.
Study NCT00182052 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosiglitazone
Description: Given orally twice daily. Participants may continue study treatment as long as their disease does not progress and they don't experience any serious side effects.
Study NCT00182052 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given orally twice daily.
Study NCT00953446 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging
Description: Performed at baseline, 2 weeks upon initiation of therapy, after cycle 2 and/or cycle 4 of therapy, and at the end of treatment
Study NCT04351464 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical therapy and reflexology
Study NCT04351464 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physical therapy and reflexology
Study NCT04154449 — intervention group
Intervention type: DRUG
Intervention: Intranasal insulin
Description: Surgical group Received intranasal insulin, the second group surgical Received placebo and the third group is non surgical do not receive anything.
Study NCT01194089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Nicotine Spray
Description: Single 3 mg dose of nasal nicotine spray
Study NCT01194089 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nasal Normal Saline Spray
Description: An isotonic solution of sodium chloride 0.65% in deionized water
Study NCT03262766 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Intermittent Hypoxia (AIH)
Description: This will consist of up to 90 seconds of 9-10% O2 (FiO2 0.09), alternating with up to 90 seconds of 21% O2 (normoxic air FiO2 0.21). The delivery of hypoxia and normoxic air mixtures will be repeated up to 18 times per session each, for a total of up to 45 minutes.
Study NCT03262766 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acute Intermittent Hypoxia (AIH)
Description: This will consist of up to 90 seconds of 9-10% O2 (FiO2 0.09), alternating with up to 90 seconds of 21% O2 (normoxic air FiO2 0.21). The delivery of hypoxia and normoxic air mixtures will be repeated up to 18 times per session each, for a total of up to 45 minutes.
Study NCT03262766 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Upper extremity training
Description: Subjects will receive 45 minutes of task-specific, high repetition upper extremity training, given using an upper-limb robotic rehabilitation device, the Armeo Spring®. Armeo Spring is a gravity support system based on an ergonomic arm exoskeleton with integrated springs. It cradles the entire arm, from shoulder to the hand, and counterbalances the weight of the user's arm. Therefore, it enhances any residual function and neuromuscular control, and assists in active movement across a large 3-D workspace. The Armeo software contains an extensive library of game-like movement exercises supported by a virtual-reality training environment that displays the functional task along with immediate performance feedback.
Study NCT03262766 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Upper extremity training
Description: Subjects will receive 45 minutes of task-specific, high repetition upper extremity training, given using an upper-limb robotic rehabilitation device, the Armeo Spring®. Armeo Spring is a gravity support system based on an ergonomic arm exoskeleton with integrated springs. It cradles the entire arm, from shoulder to the hand, and counterbalances the weight of the user's arm. Therefore, it enhances any residual function and neuromuscular control, and assists in active movement across a large 3-D workspace. The Armeo software contains an extensive library of game-like movement exercises supported by a virtual-reality training environment that displays the functional task along with immediate performance feedback.
Study NCT03262766 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham Acute intermittent hypoxia
Description: This will consist of up to 90 seconds of 21% O2 (FiO2 0.21), alternating with up to 90 seconds of 21% O2 (normoxic air FiO2 0.21). The delivery of alternating normoxic air will be repeated up to 18 times per session each, for a total of up to 45 minutes.
Study NCT03262766 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Acute intermittent hypoxia
Description: This will consist of up to 90 seconds of 21% O2 (FiO2 0.21), alternating with up to 90 seconds of 21% O2 (normoxic air FiO2 0.21). The delivery of alternating normoxic air will be repeated up to 18 times per session each, for a total of up to 45 minutes.
Study NCT03100916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 690517
Description: once daily
Study NCT03100916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: once daily
Study NCT03100916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 690517 (Reference)
Description: Fasting
Study NCT03100916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 690517
Description: Non- fasting
Study NCT00764387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadovist® (Gadobutrol, BAY86-4875)
Description: 0,1 mmol/kg of body weight in the vein, single administration
Study NCT00764387 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dotarem
Description: 0,1 mmol/kg of body weight in the vein, single administration
Study NCT02163967 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Cranial Electrical Stimulation Fisher-Wallace Stimulator (Model FW100)
Description: low voltage alternating current transcranial electrical stimulation
Study NCT01491386 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rhBMP-2/ACS/LT-CAGE® Device
Description: LT-CAGE® device with recombinant human bone morphogenetic protein-2 ( rhBMP-2) and the absorbable collagen sponge (ACS).